LPAR2

edit
Receptor lizofosfatidne kiseline 2
Identifikatori
SimboliLPAR2; EDG-4; EDG4; LPA-2; LPA2
Vanjski IDOMIM: 605110 MGI: 1858422 HomoloGene: 3465 IUPHAR: LPA2 GeneCards: LPAR2 Gene
Ontologija gena
Molekularna funkcija • vezivanje G-protein alfa podjedinice
• aktivnost G-protein spregnutog receptora
• proteinsko vezivanje
• vezivanje PDZ domena
• veivanje LIM domena
Celularna komponenta • citoplazma
• ćelijska membrana
• integralno sa ćelijskom membranom
• ćelijska površina
Biološki proces • activacija MAPK aktivnosti
• signalni put G-protein spregnutog receptora
• aktivacija fosfolipaze C
• povišenje koncentracije citozolnih jona kalcijuma
Pregled RNK izražavanja
podaci
Ortolozi
VrstaČovekMiš
Entrez917053978
EnsemblENSG00000064547ENSMUSG00000031861
UniProtQ9HBW0E9QJW6
RefSeq (mRNA)NM_004720.5NM_020028.3
RefSeq (protein)NP_004711.2NP_064412.2
Lokacija (UCSC)Chr 19:
19.73 - 19.74 Mb		Chr 8:
72.35 - 72.36 Mb
PubMed pretraga[1][2]

Receptor lizofosfatidne kiseline 2 (LPA2) je protein koji je kod ljudi kodiran LPAR2 genom.[1][2][3] LPA2 je G protein spregnuti receptor za koji se vezuje lipidni signalni molekul lizofosfatidna kiselina (LPA).[4]

Funkcija

Ovaj protein je član familije I G protein spregnutih receptora, kao i EDG familije. Ovaj protein funkcioniše kao receptor lizofosfatidne kiseline i doprinosi mobilizaciji Ca2+. To je kritični ćelijski respons na LPA, putem asocijacije sa Gi i Gq proteinima.[1]

Interakcije

LPAR2 formira interakcije sa TRIP6.[5]

Reference

  1. ↑ 1,0 1,1 „Entrez Gene: LPAR2 Lysophosphatidic acid receptor 2”. 
  2. ↑ An S, Bleu T, Hallmark OG, Goetzl EJ (April 1998). „Characterization of a novel subtype of human G protein-coupled receptor for lysophosphatidic acid”. J. Biol. Chem. 273 (14): 7906–10. DOI:10.1074/jbc.273.14.7906. PMID 9525886. 
  3. ↑ An S, Bleu T, Zheng Y, Goetzl EJ (November 1998). „Recombinant human G protein-coupled lysophosphatidic acid receptors mediate intracellular calcium mobilization”. Mol. Pharmacol. 54 (5): 881–8. PMID 9804623. 
  4. ↑ Choi JW, Herr DR, Noguchi K, Yung YC, Lee C-W, Mutoh T, Lin M-E, Teo ST, Park KE, Mosley AN, Chun J (January 2010). „LPA Receptors: Subtypes and Biological Actions”. Annual Review of Pharmacology and Toxicology 50 (1): 157–186. DOI:10.1146/annurev.pharmtox.010909.105753. PMID 20055701. [mrtav link]
  5. ↑ Xu, Jun; Lai Yun-Ju, Lin Weei-Chin, Lin Fang-Tsyr (March 2004). „TRIP6 enhances lysophosphatidic acid-induced cell migration by interacting with the lysophosphatidic acid 2 receptor”. J. Biol. Chem. (United States) 279 (11): 10459–68. DOI:10.1074/jbc.M311891200. ISSN 0021-9258. PMID 14688263. 

Literatura

  • Spiegel S (2000). „Sphingosine 1-phosphate: a ligand for the EDG-1 family of G-protein-coupled receptors.”. Ann. N. Y. Acad. Sci. 905: 54–60. DOI:10.1111/j.1749-6632.2000.tb06537.x. PMID 10818441. 
  • Contos JJ, Ishii I, Chun J (2001). „Lysophosphatidic acid receptors.”. Mol. Pharmacol. 58 (6): 1188–96. PMID 11093753. 
  • Goetzl EJ, Dolezalova H, Kong Y, et al. (1999). „Distinctive expression and functions of the type 4 endothelial differentiation gene-encoded G protein-coupled receptor for lysophosphatidic acid in ovarian cancer.”. Cancer Res. 59 (20): 5370–5. PMID 10537322. 
  • Contos JJ, Chun J (2000). „Genomic characterization of the lysophosphatidic acid receptor gene, lp(A2)/Edg4, and identification of a frameshift mutation in a previously characterized cDNA.”. Genomics 64 (2): 155–69. DOI:10.1006/geno.2000.6122. PMID 10729222. 
  • Bandoh K, Aoki J, Taira A, et al. (2000). „Lysophosphatidic acid (LPA) receptors of the EDG family are differentially activated by LPA species. Structure-activity relationship of cloned LPA receptors.”. FEBS Lett. 478 (1–2): 159–65. DOI:10.1016/S0014-5793(00)01827-5. PMID 10922489. 
  • Young KW, Bootman MD, Channing DR, et al. (2001). „Lysophosphatidic acid-induced Ca2+ mobilization requires intracellular sphingosine 1-phosphate production. Potential involvement of endogenous EDG-4 receptors.”. J. Biol. Chem. 275 (49): 38532–9. DOI:10.1074/jbc.M006631200. PMID 10954727. 
  • Zheng Y, Voice JK, Kong Y, Goetzl EJ (2001). „Altered expression and functional profile of lysophosphatidic acid receptors in mitogen-activated human blood T lymphocytes.”. FASEB J. 14 (15): 2387–9. DOI:10.1096/fj.00-0492fje. PMID 11024010. 
  • Hama K, Bandoh K, Kakehi Y, et al. (2002). „Lysophosphatidic acid (LPA) receptors are activated differentially by biological fluids: possible role of LPA-binding proteins in activation of LPA receptors.”. FEBS Lett. 523 (1–3): 187–92. DOI:10.1016/S0014-5793(02)02976-9. PMID 12123830. 
  • Strausberg RL, Feingold EA, Grouse LH, et al. (2003). „Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences.”. Proc. Natl. Acad. Sci. U.S.A. 99 (26): 16899–903. DOI:10.1073/pnas.242603899. PMC 139241. PMID 12477932. 
  • Fujita T, Miyamoto S, Onoyama I, et al. (2003). „Expression of lysophosphatidic acid receptors and vascular endothelial growth factor mediating lysophosphatidic acid in the development of human ovarian cancer.”. Cancer Lett. 192 (2): 161–9. DOI:10.1016/S0304-3835(02)00713-9. PMID 12668280. 
  • Hu YL, Albanese C, Pestell RG, Jaffe RB (2003). „Dual mechanisms for lysophosphatidic acid stimulation of human ovarian carcinoma cells.”. J. Natl. Cancer Inst. 95 (10): 733–40. DOI:10.1093/jnci/95.10.733. PMID 12759391. 
  • Xu J, Lai YJ, Lin WC, Lin FT (2004). „TRIP6 enhances lysophosphatidic acid-induced cell migration by interacting with the lysophosphatidic acid 2 receptor.”. J. Biol. Chem. 279 (11): 10459–68. DOI:10.1074/jbc.M311891200. PMID 14688263. 
  • Ota T, Suzuki Y, Nishikawa T, et al. (2004). „Complete sequencing and characterization of 21,243 full-length human cDNAs.”. Nat. Genet. 36 (1): 40–5. DOI:10.1038/ng1285. PMID 14702039. 
  • Grimwood J, Gordon LA, Olsen A, et al. (2004). „The DNA sequence and biology of human chromosome 19.”. Nature 428 (6982): 529–35. DOI:10.1038/nature02399. PMID 15057824. 
  • Oh YS, Jo NW, Choi JW, et al. (2004). „NHERF2 specifically interacts with LPA2 receptor and defines the specificity and efficiency of receptor-mediated phospholipase C-beta3 activation.”. Mol. Cell. Biol. 24 (11): 5069–79. DOI:10.1128/MCB.24.11.5069-5079.2004. PMC 416407. PMID 15143197. 
  • Gerhard DS, Wagner L, Feingold EA, et al. (2004). „The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).”. Genome Res. 14 (10B): 2121–7. DOI:10.1101/gr.2596504. PMC 528928. PMID 15489334. 

Vidi još

Spoljašnje veze

  • „Lysophospholipid Receptors: LPA2”. IUPHAR Database of Receptors and Ion Channels. International Union of Basic and Clinical Pharmacology. Arhivirano iz originala na datum 2016-03-03. 
  • MeSH Lysophospholipid+receptors
  • p
  • r
  • u
Klasa A: Rodopsinu slični
α1 (A, B, D) • α2 (A, B, C) • β1 • β2 • β3
Adenozinski (A1, A2A, A2B, A3) • P2Y (1, 2, 4, 5, 6, 8, 9, 10, 11, 12, 13, 14)
(svi osim 5-HT3) 5-HT1 (A, B, D, E, F) • 5-HT2 (A, B, C) • 5-HT (4, 5A, 6, 7)
Drugi
Acetilholin (M1, M2, M3, M4, M5) • Dopamin (D1, D2, D3, D4, D5) • Histamin (H1, H2, H3, H4) • Melatonin (1A, 1B, 1C) • TAAR (1, 2, 3, 5, 6, 8, 9)
Metaboliti i
signalni molekuli
CysLT (1, 2) • LTB4 (1, 2) • FPRL1 • OXE • Prostaglandin (DP (1, 2), EP (1, 2, 3, 4), FP) • Prostaciklin • Tromboksan
Drugi
Žučna kiselina • Kanabinoidni (CB1, CB2, GPR (18, 55, 119)) • EBI2 • Estrogen • Slobodna masna kiselina (1, 2, 3, 4) • Laktat  • Lizofosfatidna kiselina (1, 2, 3, 4, 5, 6)  • Lizofosfolipid (1, 2, 3, 4, 5, 6, 7, 8) • Niacin (1, 2) • Oksoglutarat • PAF • Sfingozin-1-fosfat (1, 2, 3, 4, 5) • Sukcinat
Peptid
B/W (1, 2) • FF (1, 2) • S • Y (1, 2, 4, 5) • Neuromedin (B, U (1, 2)) • Neurotenzin (1, 2)
Drugi
Anafilatoksin (C3a, C5a) • Angiotenzin (1, 2) • Apelin • Bombezin (BRS3, GRPR, NMBR) • Bradikinin (B1, B2) • Hemokin • Holecistokinin (A, B) • Endotelin (A, B) • Formil peptid (1, 2, 3) • FSH • Galanin (1, 2, 3) • GHB receptor • Gonadotropin-oslobađajući hormon (1, 2) • Grelin • Kispeptin • Luteinizirajući hormon/horiogonadotropin • MAS (1, 1L, D, E, F, G, X1, X2, X3, X4) • Melanokortin (1, 2, 3, 4, 5) • MCHR (1, 2) • Motilin • Opioidni (δ, κ, μ, Nociceptin & ζ, ali ne σ) • Oreksin (1, 2) • Oksitocin • Prokineticin (1, 2) • Prolaktin-oslobađajući peptid • Relaksin (1, 2, 3, 4) • Somatostatin (1, 2, 3, 4, 5) • Tahikinin (1, 2, 3) • Tirotropin • Tirotropin-oslobađajući hormon • Urotenzin-II • Vazopresin (1A, 1B, 2)
Razno
GPR (1, 3, 4, 6, 12, 15, 17, 18, 19, 20, 21, 22, 23, 25, 26, 27, 31, 32, 33, 34, 35, 37, 39, 42, 44, 45, 50, 52, 55, 61, 62, 63, 65, 68, 75, 77, 78, 81, 82, 83, 84, 85, 87, 88, 92, 101, 103, 109A, 109B, 119, 120, 132, 135, 137B, 139, 141, 142, 146, 148, 149, 150, 151, 152, 153, 160, 161, 162, 171, 173, 174, 176, 177, 182, 183)
Drugi
Adrenomedulin • Mirisni • Opsin (3, 4, 5, 1LW, 1MW, 1SW, RGR, RRH) • Proteazom-aktivirani (1, 2, 3, 4) • SREB (1, 2, 3)
Klasa B: Sekretinu slični
GPR (56, 64, 97, 98, 110, 111, 112, 113, 114, 115, 116, 123, 124, 125, 126, 128, 133, 143, 144, 155, 157)
Drugi
Klasa C: Metabotropni
glutamat / feromon
TAS1R (1, 2, 3) • TAS2R (1, 3, 4, 5, 8, 9, 10, 12, 13, 14, 16, 19, 20, 30, 31, 38, 39, 40, 41, 42, 43, 45, 46, 50)
Drugi
Klasa F:
Frizzled / Zaglađeni
Uvojiti
Frizzled (1, 2, 3, 4, 5, 6, 7, 8, 9, 10)
Zaglađeni
B trdu: peptidi (nrpl/grfl/cytl/horl), receptori (lgic, enzr, gprc, igsr, intg, nrpr/grfr/cytr), itra (adap, gbpr, mapk), calc, lipd, signalni putevi (hedp, wntp, tgfp+mapp, notp, jakp, fsap, hipp, tlrp)